EP4104851A1 - Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus - Google Patents

Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus Download PDF

Info

Publication number
EP4104851A1
EP4104851A1 EP20951308.4A EP20951308A EP4104851A1 EP 4104851 A1 EP4104851 A1 EP 4104851A1 EP 20951308 A EP20951308 A EP 20951308A EP 4104851 A1 EP4104851 A1 EP 4104851A1
Authority
EP
European Patent Office
Prior art keywords
extract
coronavirus
epazote
composition
oregano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20951308.4A
Other languages
German (de)
French (fr)
Other versions
EP4104851C0 (en
EP4104851A4 (en
EP4104851B1 (en
Inventor
Rosa Maria PORTILLO ROSADO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP23211263.1A priority Critical patent/EP4299132A3/en
Publication of EP4104851A1 publication Critical patent/EP4104851A1/en
Publication of EP4104851A4 publication Critical patent/EP4104851A4/en
Application granted granted Critical
Publication of EP4104851C0 publication Critical patent/EP4104851C0/en
Publication of EP4104851B1 publication Critical patent/EP4104851B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/21Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/22Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/36Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/79Schisandraceae (Schisandra family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • the present invention relates to antimicrobial compositions capable of inhibiting the transmission of a virus, in particular the coronavirus, and its treatment, based on a surfactant with degreasing properties, combined with natural plant extracts, as well the method of obtaining said composition.
  • the coronavirus is one of the viruses that is wreaking the most havoc across the world population.
  • a trial with a completely natural formula can reduce the risks to a minimum.
  • Patent CA2569080A from 2006 refers to the field of coronavirus and molecules for its prevention.
  • Patent CN100500162C requested by TOAGOSEI CO LTD in 2003 provides effective management of the coronavirus and can be converted into the various antiviral agent of many cleaning products, it contains a silver ion carrier antiviral agent that may inactivate the virus, but selected of chemical compound.
  • Patent CN105687226A from 2016 deals with a preparation to inhibit coronavirus infections having Astragalus as the active ingredient.
  • Patent JP2003384125A deals with an aerosol disinfectant preventing infectious disease, either by air or by direct treatment into the hands, its active ingredient is hinokitiol, aloe vera, green tea, albomarginata and houttuynia cordata, it is sprayed and said to prevent the spread of infection.
  • the mortality rate of infected people up to 40 years old is 0.2%, but among those between 70 and 79 years old it increases up to 8%, while from 80 years old and the number increases up to 14.8%.
  • the present invention aims to develop a pharmaceutical formulation obtained by combining the powdered extract obtained from aqueous extracts of different plants and a surfactant with degreasing properties as active ingredients, without side effects from its intake.
  • the present invention has as its object the formulation of different pharmaceutical dosage forms such as capsules, tea, drinkable ampoules, and injectable solution ampoules that comprise non-hydrolyzed collagen as a surfactant, (soap), powdered extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), Oregano, (Origanum vulgare), Star Anise, (Illicium verum), together with preservatives for the treatment of patients suffering from coronavirus, surprisingly obtaining a notable improvement 24 hours after starting treatment, and it has been possible to verify an integral and significant improvement at 48 hours after applying the administration regimen.
  • a surfactant such as capsules, tea, drinkable ampoules, and injectable solution ampoules that comprise non-hydrolyzed collagen as a surfactant, (soap), powdered extracts of Dandelion (Taraxacum officinal
  • Surfactants have antibacterial properties that is why they can eliminate microorganisms, due to their cleaning power.
  • collagen is the most abundant protein in our body, the main component of the tissues that make up various parts of the body, including tendons, ligaments, gums, teeth, skin and muscles.
  • the procedure for preparing these capsules includes several stages:
  • the capsules thus obtained according to the described process have a storage stability at ambient conditions of 2 years.
  • capsules obtained according to example 1 patients diagnosed with coronavirus shall be prescribe for 7 days with a dosage of three capsules per day with a composition of ingredients as follows: Non-hydrolyzed collagen 25% Dandelion extract 20% Anamu extract 10% Epazote extract 15% Oregano extract 19.5% Star anise extract 10% Sodium benzoate 0.25% Potassium sorbate 0.25%
  • the homogeneous powder obtained according to steps 1 to 5 previously described in the procedure for obtaining the capsules is now packed in bags or sacks of porous paper, silk or nylon, similar to those used in tea bags from which it is prepared. an infusion with hot water useful in the treatment of coronavirus.
  • the bags obtained according to the described process have a storage stability at ambient conditions of 2 years.
  • the procedure for the preparation of drinkable ampoules consists of the following steps:
  • the ampoules of injectable solution thus obtained according to the described process have an ambient storage stability of 2 years.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions and pharmaceutical forms for the treatment and prevention of coronavirus, which contain in its formulation non-hydrolyzed collagen as a surfactant with degreasing properties and natural active ingredients in the form of hydrolyzed powders of aqueous extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), oregano (Origanum vulgare), star anise (Lllicium verun) together with preservatives, as well as the obtaining and preparation procedures associated with the development of the different compositions and pharmaceutical forms.

Description

    FIELD OF INVENTION
  • The present invention relates to antimicrobial compositions capable of inhibiting the transmission of a virus, in particular the coronavirus, and its treatment, based on a surfactant with degreasing properties, combined with natural plant extracts, as well the method of obtaining said composition.
  • BACKGROUND OF THE INVENTION
  • The coronavirus is one of the viruses that is wreaking the most havoc across the world population.
  • Much is said about it, but until now we have not achieved a medicine or a vaccine capable of preventing and controlling it.
  • Every day new expectations of studies appear, but none that we can affirm with property this is what stops it.
  • The damage caused to both humanity and the economy is incalculable.
  • But we cannot drink a shampoo or a cleansing gel due to its harmful effects on health, and its consequences, but that would be a solution.
  • One of the great inconveniences that arise is that there are times when the coronavirus does not present any symptoms, which is the main danger since a large group of people can be infected without even knowing it.
  • Given the death rate from this disease, saving time is a must.
  • A trial with a completely natural formula can reduce the risks to a minimum.
  • Patent CA2569080A from 2006 refers to the field of coronavirus and molecules for its prevention.
  • Patent CN100500162C requested by TOAGOSEI CO LTD in 2003 provides effective management of the coronavirus and can be converted into the various antiviral agent of many cleaning products, it contains a silver ion carrier antiviral agent that may inactivate the virus, but selected of chemical compound. Patent CN105687226A from 2016 deals with a preparation to inhibit coronavirus infections having Astragalus as the active ingredient.
  • Patent JP2003384125A from 2003 deals with an aerosol disinfectant preventing infectious disease, either by air or by direct treatment into the hands, its active ingredient is hinokitiol, aloe vera, green tea, albomarginata and houttuynia cordata, it is sprayed and said to prevent the spread of infection.
  • Tests pose complex ethical situations, but for these unusual situations, we will have to look for unusual solutions as well.
  • It is known that the people with the lowest risk of death or developing a severe form of the disease are young people without pre-existing health conditions.
  • Older people are the most at risk. The mortality rate increases exponentially from the age of 65, approximately.
  • In China, for example, the mortality rate of infected people up to 40 years old is 0.2%, but among those between 70 and 79 years old it increases up to 8%, while from 80 years old and the number increases up to 14.8%.
  • Fortunately, so far, no children have died from coronavirus.
  • Evidently, there are children who are also infected with the virus, but they do not get sick, or only show slight symptoms.
  • Much has been said about the causes, but nothing that gives an answer to it yet.
  • DESCRIPTION OF THE INVENTION
  • The present invention aims to develop a pharmaceutical formulation obtained by combining the powdered extract obtained from aqueous extracts of different plants and a surfactant with degreasing properties as active ingredients, without side effects from its intake.
  • More particularly, the present invention has as its object the formulation of different pharmaceutical dosage forms such as capsules, tea, drinkable ampoules, and injectable solution ampoules that comprise non-hydrolyzed collagen as a surfactant, (soap), powdered extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), Oregano, (Origanum vulgare), Star Anise, (Illicium verum), together with preservatives for the treatment of patients suffering from coronavirus, surprisingly obtaining a notable improvement 24 hours after starting treatment, and it has been possible to verify an integral and significant improvement at 48 hours after applying the administration regimen.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Currently there is no pharmaceutical formula that contains a surfactant with degreasing properties as a base and that can be ingested at the same time.
  • We have achieved a formula that contains a surfactant with degreasing properties and can be taken without side effects, with the benefit of preventing the virus from surviving. We are facing a great solution for the world.
  • So far, the only thing that has been shown to stop and delay its spread is soap, because coronaviruses are wrapped in a lipid layer that soap inhibits.
  • It is known that washing body parts, Ex. washing hands and hard surfaces, countertops and sinks can significantly decrease the population of microorganisms including pathogens. Coronaviruses have a lipid membrane that gives the particle relatively low stability, especially when compared to the naked particle of the common cold virus. That makes it relatively easy to remove them from your hands using soapy solutions.
  • Therefore, protection seems simple, social distance and use of soap.
  • Surfactants have antibacterial properties that is why they can eliminate microorganisms, due to their cleaning power.
  • What we can see is that there is a relationship with the production and decrease of collagen. When collagen is at its maximum production, the incidence is very slight, but it increases as well as its production decreases, which is why it attacks the elderly more strongly since they do not produce collagen at that age.
  • We know that collagen is the most abundant protein in our body, the main component of the tissues that make up various parts of the body, including tendons, ligaments, gums, teeth, skin and muscles.
  • As a result of the tests carried out, we were able to verify that when using plant extracts with non-hydrolyzed collagen for their surfactants and degreasing power, (as detailed in patent P- 2019-0173 filed in 2019 by Rosa Maria Portillo and in the process of approval) when ingested, the spread of the coronavirus is inhibited, since the formulation, having this surfactant and the molecule not being hydrolyzed, is larger in size and makes its absorption much slower, being able to inhibit the virus in the intestinal tract. Since the only thing that inhibits it so far is soap, when ingesting the formulation it destroys the lipid layer of the virus, when mixed with plant extracts, it potentiates the effect of the other elements.
  • Which comes to solve the problem that we are experiencing at the moment, in this case a product of covid-19, since this would be the only pharmaceutical formulation that contains a degreaser in its formulation and that can be ingested without side effects, either in a tea for the elderly, one capsule, one drinkable ampoule, one injectable ampoule.
  • The fundamental ingredients that are combined in the composition, as well as the functions that they fulfill within the composition are the following:
    • Non-hydrolyzed collagen:
      It is a natural active ingredient and a key protein in the human body, not hydrolyzed it is a surfactant with degreasing and cleansing properties, and as it is not hydrolyzed the molecule is larger which will make the process of crossing the intestinal barrier slower, with which can inhibit the virus in the intestinal tract.
    • Dandelion:
      It contains high levels of the antioxidant beta-carotene, which provides strong protection against cell damage and oxidative stress, prevents bleeding in the liver, and contributes to blood cleansing. It protects liver tissue, and has diuretic properties widely used in kidney problems.
    • Anamu:
      It is analgesic and anti-inflammatory in various skin conditions.
    • Epazote
      • It is a natural antiparasitic, has calming and relaxing properties.
      • It is used to treat stomach problems such as diarrhea, vomiting, and stomach pain. Helps treat flu and cough.
    • Oregano:
      With properties for conditions of the respiratory system with congestion, due to its anti-inflammatory, analgesic and antiseptic effect and it has an antimicrobial effect.
    • Star anise:
      Used for spasms of the stomach and gallbladder. With antibacterial and fungicidal active ingredients, used to treat flu, bronchitis, cough and asthma.
    • Sodium benzoate:
      • preservative
      • Potassium sorbate:
      • Preservative.
  • The qualitative and quantitative composition by weight of the active ingredients, solvents and preservatives proposed in this formulation, as well as their function within the composition, is as follows:
    Non-hydrolyzed collagen 1%-35% Surfactants
    Dandelion extract 5%-30% Active ingredient
    Epazote extract 3%-20% Active ingredient
    Oregano extract 3%-20% Active ingredient
    Star anise extract 5%- 25% Active ingredient
    Sodium benzoate 1%-15% Preservative
    Potassium sorbate extract 0.25% Preservative
    Treated water 15%-19.5% Solvent
  • PROCEDURE FOR THE CAPSULES ELABORATION
  • The procedure for preparing these capsules includes several stages:
    1. 1. In the first stage of the process, the different raw materials are prepared, which entails the inspection, classification, and approval of the raw material to be used in the production of the final product, which will reach a final product in powder form. which is filled into hard gelatin capsules.
    2. 2. After the raw materials have been approved in the raw material reception area, they go to the pre-production area where they are prepared for entry into the production area. It is in this area where the shell is removed from those raw materials that require it, as well as the seeds, are cleaned and rinsed with treated water from the treatment plant.
    3. 3. When the raw materials leave this area, they enter the production area where they enter a stainless-steel mixer with temperature control, which is fed with steam from a Pyro-tubular boiler, which allows the temperature to be increased. in the same. In this mixer we add all the raw materials of the formula except for the non-hydrolyzed collagen and the preservatives, because these must be added in the final stage of the process at a temperature of 30°C to 40°C to avoid their degradation by temperature and then they are damage the product over time.
      In this mixer, the different raw materials, all mixed within it, are subjected to a temperature of 96°C (205°F), followed by periods of agitation every 5 minutes, with the aim that at that temperature the water can absorb the properties and nutrients from each of the raw materials present in the mixer, this will allow us to obtain a well-charged liquid, rich in all the properties from the herbs, fruits and raw materials that were subjected in this part of the production process.
    4. 4. The resulting liquid that comes out of the mixer now goes to another piece of equipment called a pressure filter. It is in this equipment that even the smallest solid particle that may be mixed with the liquid extract is separated. The objective in this part of the process is to obtain a liquid free of solid particles. At this stage we will take the opportunity to add the collagen and the Preservatives.
    5. 5. The filtered liquid passes to a Spray Dryer ADL 311 type spray dryer or spray dryer. At this stage of the process, what is achieved is that the liquid from the pressure filter turns into powder. The feed of the concentrated and filtered liquid is fed by means of a peristaltic pump with a silicone hose, this spray equipment has a temperature system, spray system at the tip of the outlet nozzle, blower, heater, suction filter and exhaust filter, through which it performs the drying and subsequent spraying of the liquid, converting it into powder.
    6. 6. The powder obtained in the Pulverization equipment now goes to a NJP 1200D Encapsulating Machine, which is an automatic machine that allows the powdered product to be encapsulated in Gelatin Capsules, which can be #0 Gelatin Capsules, for example, in #0 Red/Black hard gelatin capsules from ACG Associated Capsules Pvt Ltd.
    7. 7. Once the product is encapsulated, these capsules will now go to a piece of equipment called the SP-G100 Capsule Packing Machine. The objective to be achieved in this equipment is to place the capsules in the final package, which will serve as a vehicle to make get the product to the final consumer.
  • The capsules thus obtained according to the described process have a storage stability at ambient conditions of 2 years.
  • Example 1.
  • With the capsules obtained according to example 1, patients diagnosed with coronavirus shall be prescribe for 7 days with a dosage of three capsules per day with a composition of ingredients as follows:
    Non-hydrolyzed collagen 25%
    Dandelion extract 20%
    Anamu extract 10%
    Epazote extract 15%
    Oregano extract 19.5%
    Star anise extract 10%
    Sodium benzoate 0.25%
    Potassium sorbate 0.25%
  • PROCEDURE FOR THE PREPARATION OF TEA BAGS
  • The homogeneous powder obtained according to steps 1 to 5 previously described in the procedure for obtaining the capsules is now packed in bags or sacks of porous paper, silk or nylon, similar to those used in tea bags from which it is prepared. an infusion with hot water useful in the treatment of coronavirus. The bags obtained according to the described process have a storage stability at ambient conditions of 2 years.
  • Example 2.
  • Based on my personal experience:
    I was the first model for the study, the symptoms began, I felt a dry cough, shortness of breath, diarrhea, body aches, tiredness. the rash all over my belly and back I knew I was infected, I took the test, it was positive. I am a high-risk patient, 60 years old, high blood sugar, high blood pressure, too many factors against me. I prepared the formula mentioned below, I refrained from taking any medication, only my formula, surprisingly the symptoms had begun to disappear within hours, the pain went away, I began to breathe normally, the diarrhea disappeared, the hardest thing was the rash on the body, which was completely eliminated within two days of taking the formula.
  • I only had to drink for 7 days, 2 cups a day, of the following composition of ingredients:
    Non-hydrolyzed collagen 30%
    Dandelion 15%
    Anamu 15%
    Epazote 17%
    Oregano 15%
    Star anise extract 7.50%
    Sodium benzoate 0.25%
    Potassium sorbate 0.25%
  • PROCEDURE FOR THE PREPARATION OF DRINKABLE AMPOULES
  • The procedure for the preparation of drinkable ampoules consists of the following steps:
    1. 1. In the first stage of the process, the different raw materials are received at the plant, which will go through an inspection, classification, and approval process to be used in the production of our final product, which will be drinkable ampoules.
    2. 2. After the raw materials have been approved in the raw material reception area, they go to the pre-production area where they are prepared for entry into the production area. It is in this area where the shell is removed from those materials. raw materials that require it, as well as the seeds, are cleaned and rinsed with treated water from the treatment plant.
    3. 3. When the raw materials leave this area, they enter the production area where the first equipment or unit operation they enter is a stainless-steel mixer with temperature control, which is fed with steam, which allows to achieve the increase of the temperature in it. In this mixer we add all the raw materials of our formula, except the non-hydrolyzed collagen and the preservatives, because these must be added at a temperature of 30°C to 40°C to avoid their degradation due to high temperatures and that later they do not can have the expected effect on the final product.
    4. 4. In this mixer, the different raw materials, all mixed within it, are subjected to a temperature of 96°C (205°F), followed by periods of agitation every 5 minutes, with the aim that at that temperature the water can absorb the properties and nutrients of each of the raw materials present in the mixer, this will allow us to obtain a well-charged liquid, rich in all the properties from the herbs, fruits and raw materials that were subjected in this part of the production process.
    5. 5. The resulting liquid that comes out of the mixer now goes to another piece of equipment called a pressure filter. It is in this equipment that even the smallest solid particle that may be mixed with the liquid extract is separated. The objective in this part of the process is to obtain a liquid free of solid particles. At this stage we will take the opportunity to add the non-hydrolyzed collagen and the preservatives.
    6. 6. The container chosen to store the final product is the container: Special Ampoules for Drinkable Solutions.
    7. 7. These containers are subjected to an automatic washing process in a machine that provides a pressurized water jet, this water is totally purified.
    8. 8. Once these containers leave the washing process, they enter a sterilization machine or dryer that will be in charge of sterilizing and drying the containers through the action of high temperatures.
    9. 9. Upon leaving the sterilization or drying machine, these containers enter an SCT Pharma oven, where the dehydrogenation process will be carried out, which is nothing more than the process that will allow us to reduce the total or almost total endotoxins. Bacterial (Pyrogens), in other words what we are looking for is to obtain blisters free of all microorganisms and undesirable pathogenic substances, we achieve this through processes that use high temperatures, such as those that have been previously exposed.
    10. 10. The resulting solution obtained in step 5. From the filter. You will now move on to a piece of equipment called a vial filling and sealing machine. The objective in this step is to dose the filtered solution as quickly as possible into the drinkable ampoules, taking care not to wet the neck of the ampoules. This machine will subsequently be responsible for sealing the valves, since it has a sealing system for this type of ampoules.
    11. 11. The next stage is the stage called labeling, stage in which the label is placed on the product including elementary information such as: Lot number, Dosage, Manufacturing Date, Expiration Date, etc.
    12. 12. In the final stage of our process, we find the storage of our finished product, under favorable conditions of temperature and humidity, characteristic of this type of product. The drinkable ampoules thus obtained according to the process described have an ambient storage stability of 2 years.
    Example 3.
  • Patients with coronavirus must undergo treatment for a period of 7 days and with a dosage of 3 drinkable ampoules per day, with a composition of ingredients per ampule of:
    Properly treated water 19.5%
    Non-hydrolyzed collagen 35%
    Dandelion Extract 10%
    Anamu extract 8%
    Epazote 12%
    Oregano 10%
    Star anise 5%
    Sodium benzoate 0.25%
    Potassium Sorbate 0.25%
  • PROCEDURE FOR THE PREPARATION OF AN INTRAMUSCULAR INJECTABLE SOLUTION
  • The procedure for the preparation of an intramuscular injectable solution consists of the following steps:
    1. 1. On the first stage of the process, the different raw materials are received at the plant, which will go through an inspection, classification, and approval process to be used in the production of our final product, which will be an intramuscular injectable solution.
    2. 2. After the raw materials have been approved in the raw material reception area, they go to the pre-production area where they are prepared for entry into the production area. It is in this area where the shell is removed from those materials. raw materials that require it, as well as the seeds, are cleaned and rinsed with treated water from the treatment plant.
    3. 3. When the raw materials leave this area, they enter the production area where the first equipment or unit operation they enter is a stainless-steel mixer with temperature control, which is fed with steam, which allows to achieve the increase of the temperature in it. In this mixer we add all the raw materials of our formula, except for the non-hydrolyzed collagen, the lidocaine, the preservative and the ascorbic acid, because these must be added at a temperature of 30°C to 40°C to avoid their degradation by high temperatures and then cannot have the expected effect on the final product.
    4. 4. The different raw materials are placed in this mixer, all mixed within it, they are subjected to a temperature of 96°C (205°F), followed by periods of agitation every 5 minutes, with the aim that at that temperature the water can absorb the properties and nutrients of each of the raw materials present in the mixer, this will allow us to obtain a well-charged liquid, rich in all the properties from the herbs, fruits and raw materials that were subjected in this part of the production process .
    5. 5. The resulting liquid that comes out of the mixer now goes to another piece of equipment called a pressure filter. It is in this equipment that even the smallest solid particle that may be mixed with the liquid extract is separated. The objective in this part of the process is to obtain a liquid free of solid particles. In this stage we will take the opportunity to add those pending products that we did not add in the previous stage due to the high temperatures, these are the non-hydrolyzed collagen, the preservative, the lidocaine and the ascorbic acid.
    6. 6. The container chosen to store the final product is the container: Glass Ampoule for Injectable Solutions.
    7. 7. These containers are subjected to an automatic washing process in a machine that provides a pressurized water jet, this water is totally purified.
    8. 8. Once these containers leave the washing process, they enter a sterilization machine or dryer that will be in charge of sterilizing and drying the containers through the action of high temperatures.
    9. 9. Upon leaving the sterilization or drying machine, these containers enter an SCT Pharma oven, where the depyrogenation process will be carried out, which is nothing more than the process that will allow us to reduce the total or almost total endotoxins. Bacterial (Pyrogens), in other words what we are looking for is to obtain blisters free of all microorganisms and undesirable pathogenic substances, we achieve this through processes that use high temperatures, such as those that have been previously exposed.
    10. 10. The resulting solution that we obtained in step 5, coming from the filter, will now pass to a piece of equipment called the Vial Filling and Sealing Machine. The objective in this step is to dose the filtered solution as quickly as possible into the glass ampoules, taking care always not to wet the neck of the blisters. This stage will end with the injection of inert gas. This machine will later be in charge of sealing the valves, since it has a sealing system for glass-type ampoules, which were the types of packaging chosen in our process.
    11. 11. Once we have the glass ampoules ready, containing the product inside and duly sealed, they are sterilized, this with the aim of eliminating any possible microorganism or contamination that may have remained on the outside of the container during the process, for which uses a sterilization equipment called an autoclave, the process that is carried out in this equipment is sterilization by moist heat, in which this equipment uses saturated water vapor, at a pressure of 15 pounds, which allows the chamber to reach a temperature of 121°C, in this equipment the ampoules will last about 15 minutes going through the sterilization process.
    12. 12. The next stage is the stage called labeling, stage in which the label is placed on the product including basic information such as: batch number, dose, route of administration, manufacturing date, expiration date. The ampoules of injectable solution thus obtained. The next stage is the stage called labeling, stage in which the label is placed on the product including basic information such as: Lot number, Dosage, Manufacturing Date, Expiration Date, etc.
  • The ampoules of injectable solution thus obtained according to the described process have an ambient storage stability of 2 years.
  • Example 4.
  • Patients positive for coronavirus will undergo treatment for a period of 7 days with a dosage of 3 ampoules of intramuscular injectable solution per day. with a composition of ingredients per ampoule of:
    Properly treated water 18.5%
    Non-hydrolyzed collagen 24%
    Dandelion 13%
    Anamu 18%
    Epazote 8%
    Oregano 8%
    Star anise 8.51%
    Lidocaine 1.8% anesthetic
    Benzoic Acid 0.17% preservative
    Ascorbic acid 0.02% antioxidant
  • A group of 5 patients was taken and they were evaluated through a self-assessment of their condition before starting the plan and after 7 days of treatment with two cups of tea a day, for this assessment they were asked to rate 1 On the 5th, his improvement with respect to his situation at the beginning of the treatment, the parameters to be assessed were muscle pain, dry cough, shortness of breath, diarrhea, tiredness, loss of the sense of smell and taste, body rash and fever. The following table shows the results of the self-assessment of their improvement with the tea treatment. Table No. 1 Tabulation of the self-assessment of a sample of 5 patients in the improvement of their individual coronavirus status with treatment for 7 days with the tea object of the present invention, assessment of the improvement with a weighting from 1 to 5.
    Patient Headaches and muscle aches Cough and shortness of breath Loss of smell and taste Diarrhea and fever
    Before Assessment Before Assessment Before Assessment Before Assessment
    1 Yes 5 Yes 5 Yes 5 Yes 5
    2 Yes 5 Yes 5 Yes 5 Yes 5
    3 Yes 4 Yes 5 Yes 4 Yes 5
    4 Yes 5 Yes 5 no 0 Yes 5
    5 Yes 5 Yes 5 Yes 4 Yes 5
    Average rating improvement 4.80 5 4.50 5
  • The results obtained from the self-assessment that each patient who underwent the tea treatment where no other medication was taken for the relief of covid-19.
  • To be sure of its effectiveness, I was infected four times and the four times taking the formulation the symptoms disappeared with a proven improvement in 24 hours, the action of the formulation is one hundred percent effective, and does not carry any risk for the patient, with the advantage that it can be taken as prevention before being in places where there are people together without side effects, say an airplane; a restaurant; a cinema; since the virus would be inhibited by ingesting it. In 7 days, the person is recovered and it is a clear sign that the mechanism of action of these active ingredients disables the virus. Negative collateral reactions were manifested in none of the patients who received the treatment.
  • We are facing a simple but great solution to this pandemic, soap is the only thing that inhibits it, and drinking it is the only solution.

Claims (11)

  1. Pharmaceutical composition for the treatment and prevention of coronavirus whose formulation contains as ingredients non-hydrolyzed collagen as a surfactant with degreasing properties together with natural active ingredients in the form of lyophilized powders of aqueous extracts characterized in that it comprises Dandelion (Taraxacum officinale), Anamú (Petiveria Alliacea), Epazote (Dysphania ambrosioides), Oregano (Origanum vulgare), star anise (Lllicium verun), together with preservatives.
  2. The composition of claim 1, characterized by the following list of ingredients: Non-hydrolyzed collagen 1% up to 35% Dandelion extract 5% up to 30% Anamu extract 3% up to 20% Epazote extract 3% up to 20% Oregano extract 5% up to 25% Star anise extract 1% up to 15% Sodium benzoate 0.25% Potassium sorbate 0.25%
  3. The composition of claim 1 which for oral administration is formulated in a hard gelatin capsule comprising: Non-hydrolyzed collagen 25% Dandelion extract 20% Anamu extract 10% Epazote extract 15% Oregano extract 19.5% Star anise extract 10% Sodium benzoate 0.25% Potassium sorbate 0.25%
  4. The composition of claim 1 that for its administration in the form of tea or infusion is formulated in a bag or sack of porous paper, silk or nylon to be dissolved in a rate of hot water comprising: Non-hydrolyzed collagen 30% dandelion extract 15% anamu extract 15% Epazote extract 17% Oregano extract 15% Star anise extract 7.50% Sodium benzoate 0.25% Potassium sorbate 0.25%
  5. The composition of claim 1 that for oral administration is formulated in drinkable ampoules, comprising: Properly treated water 19.5% Non-hydrolyzed collagen 35% Dandelion Extract 10% Anamu Extract 8% Epazote Extract 12% Oregano extract 10% Star anise extract 5% Sodium benzoate 0.25% Potassium sorbate 0.25%
  6. The composition of claim 1 for its administration is formulated in an intramuscular injectable solution, comprising: Properly treated water 18.5% Non-hydrolyzed collagen 24% Dandelion extract 13% Anamu Extract 18% Epazote Extract 8% Oregano extract 8% Star anise extract 8.51% Lidocaine 1.8% anesthetic Benzoic Acid 0.17% Ascorbic acid 0.02%
  7. Procedure for obtaining the active ingredients of the products characterized by the following steps:
    I. Inspection, classification, and approval of the raw material.
    II. Separation of shell and seeds to those raw materials that require it.
    III. Mixing of the raw materials with temperature control at 96°C (205°F), and stirring every 5 minutes.
    IV. Filtering and addition of preservatives.
    V. Homogenized spraying of the active ingredients and preservatives.
    VI. Preparation of the pharmaceutical form that is selected from: capsule, tea, drinkable ampoules or intramuscular injectable solution.
  8. The use of a composition according to claim 3 for the manufacture of a medicament for oral administration in the form of capsules characterized for the treatment and prevention of coronavirus.
  9. The use of a composition according to claim 4 for the manufacture of a medicament for oral administration in the form of tea or infusion for the treatment and prevention of coronavirus.
  10. The use of a composition according to claim 5 for the manufacture of a medicament for oral administration in the form of drinkable ampoules for the treatment and prevention of coronavirus.
  11. The use of a composition according to claim 6 for the manufacture of a medicament for intramuscular administration for the treatment and prevention of coronavirus.
EP20951308.4A 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus Active EP4104851B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23211263.1A EP4299132A3 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/058079 WO2022043738A1 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP23211263.1A Division EP4299132A3 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus
EP23211263.1A Division-Into EP4299132A3 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

Publications (4)

Publication Number Publication Date
EP4104851A1 true EP4104851A1 (en) 2022-12-21
EP4104851A4 EP4104851A4 (en) 2023-03-01
EP4104851C0 EP4104851C0 (en) 2023-12-27
EP4104851B1 EP4104851B1 (en) 2023-12-27

Family

ID=80354728

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23211263.1A Pending EP4299132A3 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus
EP20951308.4A Active EP4104851B1 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP23211263.1A Pending EP4299132A3 (en) 2020-08-29 2020-08-29 Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

Country Status (10)

Country Link
US (1) US20230057094A1 (en)
EP (2) EP4299132A3 (en)
CO (1) CO2022010604A2 (en)
CR (1) CR20220414A (en)
DO (1) DOP2022000178A (en)
EC (1) ECSP22066025A (en)
ES (1) ES2975224T3 (en)
MX (1) MX2022009370A (en)
PE (1) PE20231359A1 (en)
WO (1) WO2022043738A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037296A1 (en) 2003-10-16 2005-04-28 Toagosei Co., Ltd. Anti-coronavirus agent
CA2569080A1 (en) 2006-11-20 2008-05-20 Institut Pasteur Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus
CN105687226B (en) 2016-01-27 2018-04-13 中国人民解放军疾病预防控制所 A kind of preparation for being used to suppress coronavirus infection
CN111281914A (en) * 2020-02-16 2020-06-16 丁虹 Traditional Chinese medicine composition for treating pneumonia
CN111467414A (en) * 2020-02-18 2020-07-31 上海蓝盎医学科技发展有限公司 A Chinese medicinal composition for treating new coronavirus, and its preparation method
CN111298049A (en) * 2020-04-22 2020-06-19 南昌大学第一附属医院 Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof
CN111407859A (en) * 2020-04-29 2020-07-14 北京天然风尚健康科技有限公司 Preparation method and application of armor essential oil composition with antibacterial and antiviral effects
CN111569010B (en) * 2020-05-06 2021-08-20 石家庄市第五医院 Traditional Chinese medicine composition and application thereof in preparation of medicine for treating neocoronary pneumonia
CN111534877B (en) * 2020-06-04 2021-01-15 广州市中诚新型材料科技有限公司 Compound Chinese medicinal multifunctional antibacterial fiber for resisting coronavirus and influenza virus

Also Published As

Publication number Publication date
PE20231359A1 (en) 2023-09-05
EP4104851C0 (en) 2023-12-27
CO2022010604A2 (en) 2022-10-11
ES2975224T3 (en) 2024-07-04
DOP2022000178A (en) 2022-11-15
CR20220414A (en) 2022-09-15
EP4299132A2 (en) 2024-01-03
MX2022009370A (en) 2022-09-02
EP4104851A4 (en) 2023-03-01
US20230057094A1 (en) 2023-02-23
EP4299132A3 (en) 2024-02-21
EP4104851B1 (en) 2023-12-27
ECSP22066025A (en) 2022-09-30
WO2022043738A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CN106668832B (en) Application of polypeptide in preparation of medicine for treating enterovirus infection
AU2018349244B2 (en) N-acetylneuraminic acid compositions and methods of use
RU2568582C1 (en) Method for non-specific immunoprophylaxis of bovine respiratory diseases
CN103142948A (en) Medicine for preventing and treating respiratory diseases, and its preparation method
CN102319288B (en) Pure traditional Chinese medicine composition for treating poultry infectious bursal disease and preparation method thereof
EP4104851B1 (en) Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus
KR20220161413A (en) Sialic acid compositions for use in inhibiting and treating coronavirus infections
Saaty Grapefruit seed extracts’ antibacterial and antiviral activity: Anti-severe acute respiratory syndrome coronavirus 2 impact
CN110327423A (en) A kind of anti-inflammatory spray of the department of stomatology containing bletilla striata extract ingredient and larynx section
CN101328457A (en) Antibiotic antivirus perfumed soap containing oil of aromatic turmeric ingredient
KR102252009B1 (en) Antiviral or antibacterial composition containing extracts of Torreya nucifera leaf
CN107913234A (en) A kind of savatier monochasma herb toothpaste and preparation method thereof
CN111450298A (en) Marine brown algae oligosaccharide herbal atomizing agent and preparation method thereof
WO2021212269A1 (en) Application of ellagic acid in preventing and treating novel coronavirus infection
CN106344453A (en) Novel acne cream and preparation method thereof
CN112402500A (en) Application of traditional Chinese medicine preparation in preventing and killing coronavirus
CN113350487A (en) Antiviral composition and preparation method and application thereof
CN109498735A (en) Medicine for treating mosquito bites and preparation method thereof
US20230102810A1 (en) The use of unripened green mangifera indica as a natural preparation to treat sars-cov-2
CN103356698B (en) Composite mineral active-state bath agent
WO2017110767A1 (en) Anti-norovirus composition and utilization thereof
US20230285487A1 (en) Pharmaceutical composition based on plant extracts for the treatment of fibromyalgia, rheumatoid arthritis, lupus and other autoimmune diseases
US11564967B1 (en) Oral compositions containing extracts of a betel leaf and related methods
CN106362017A (en) Traditional Chinese medicine disinfectant and preparation method thereof
CN115089634A (en) Bezoar/essential oil composition for preventing and treating new coronary pneumonia, preparation method and application

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

A4 Supplementary search report drawn up and despatched

Effective date: 20230201

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/12 20060101ALI20230126BHEP

Ipc: A61K 9/08 20060101ALI20230126BHEP

Ipc: A61K 9/14 20060101ALI20230126BHEP

Ipc: A61K 9/48 20060101ALI20230126BHEP

Ipc: A61K 36/36 20060101ALI20230126BHEP

Ipc: A61K 36/79 20060101ALI20230126BHEP

Ipc: A61K 36/53 20060101ALI20230126BHEP

Ipc: A61K 36/22 20060101ALI20230126BHEP

Ipc: A61K 36/288 20060101ALI20230126BHEP

Ipc: A61K 38/39 20060101AFI20230126BHEP

17Q First examination report despatched

Effective date: 20230213

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTG Intention to grant announced

Effective date: 20231031

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020023631

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20240111

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240327

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240427

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2975224

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240427

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

U20 Renewal fee paid [unitary effect]

Year of fee payment: 5

Effective date: 20240902

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240815

Year of fee payment: 5